- Home
- MFIN vs GLSI Comparison
MFIN vs GLSI Comparison
Compare MFIN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | GLSI |
|---|---|---|
| Founded | 1995 | 2006 |
| Country | United States | United States |
| Employees | 179 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.7M | 267.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MFIN | GLSI |
|---|---|---|
| Price | $11.96 | $17.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $11.00 | ★ $57.00 |
| AVG Volume (30 Days) | 51.4K | ★ 88.7K |
| Earning Date | 10-28-2026 | 11-13-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.10 | N/A |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $7.78 |
| 52 Week High | $12.26 | $34.10 |
Technical Indicators
Market Signals| Indicator | MFIN | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 52.58 | 54.23 |
| Support Level | $11.39 | $17.96 |
| Resistance Level | $12.26 | $19.97 |
| Average True Range (ATR) | 0.31 | 1.30 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 61.73 | 55.64 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.